FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

 

Report of Foreign Private Issuer

 

 

Pursuant to Rule 13a‑16 or 15d‑16

under the Securities Exchange Act of 1934

 

 

 

For the month of May 2010

 

Commission File Number            0-16174        

 

 

 

          Teva Pharmaceutical Industries Limited          

(Translation of registrant's name into English)

 

 

5 Basel Street, P.O. Box 3190

          Petach Tikva 49131  Israel          

 

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):                             

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):                              

 

 

 

__1__ 

            Website: www.tevapharm.com

 

 

For immediate release

 

WEBCAST ALERT -FOR IMMEDIATE RELEASE

 

 

 

TEVA TO PRESENT AT THE DEUTSCHE BANK 35^TH ANNUAL

HEALTH CARE CONFERENCE

 

Jerusalem, May 3, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Deutsche Bank 35^th Annual Health Care Conference with William Marth, President & CEO, Teva North America, presenting on Wednesday, May 5, 2010.

 

 

What: Teva Presentation at the Deutsche Bank 35^th Annual Health Care Conference

 

Who: William Marth, President & CEO, Teva North America

 

When: Wednesday, May 5, 2010 at 10:40 AM (ET)

 

Where:   http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TEVA&item_id=3010209 or http://www.tevapharm.com/financial/

 

How: Live over the Internet -- log onto the Web at the address above and register for the event (approx. 10 minutes before).  An archive of the webcast will be available on Teva's website.

 

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.

 

 

###

 

 

 

 

 

 

 

 

 

Teva Pharmaceutical Industries Ltd. Web Site: www.tevapharm.com

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

 

 

 

By: /s/  Eyal Desheh

Name: Eyal Desheh
Title: Chief Financial Officer

 

Date May 3, 2010

 

 

 

 

 

 

 

 

 

 

 

__2__